Haemonetics Corp (HAE) Stock
Fundamentals
Source: third-party data provider, as of October 12, 2026
Compare with HAE
Recent news
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
HAE
PAHC vs. HAE: Which Stock Is the Better Value Option?
PAHC vs. HAE: Which Stock Is the Better Value Option?
HAE
Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?
Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?
HAE
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
HAENews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 74.50
- MACD 12/26/9
- 2.76
- EMA 9 of MACD
- 2.02
- MACD histogram
- 0.74
- SMA 50
- $101.61
- Price above SMA 50
- EMA 50
- $100.60
- Price above EMA 50
- SMA 200
- $75.75
- Price above SMA 200
- EMA 200
- $81.25
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 7 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2026Earnings
The market is expecting earnings per share of $1.20 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
HAEPAHC vs. HAE: Which Stock Is the Better Value Option?
PAHC vs. HAE: Which Stock Is the Better Value Option?
HAEHaemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?
Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?
HAEPAHC vs. HAE: Which Stock Should Value Investors Buy Now?
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
HAE
HAE, TWST Stocks Jump To Over 5-Year Highs – What’s Driving The Gains Today?
HAE, TWST Stocks Jump To Over 5-Year Highs – What’s Driving The Gains Today?
HAE
GEHC vs. HAE: Which Stock Is the Better Value Option?
GEHC vs. HAE: Which Stock Is the Better Value Option?
HAE
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
HAE
Here's Why Haemonetics (HAE) is a Strong Momentum Stock
Here's Why Haemonetics (HAE) is a Strong Momentum Stock
HAE
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
HAE
HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up
HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up
HAENews tone: automated (AI) classification of the article's content, not a price prediction.
About Haemonetics Corp
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Christopher A. Simon | CEO, President & Director | 1964 |
| Mr. James C. D'Arecca CPA | CFO, Executive VP & Financial Officer | 1971 |
| Mr. Frank W. Chan Ph.D. | Executive VP & COO | 1970 |
| Ms. Michelle L. Basil Esq., J.D. | Executive VP, General Counsel & Secretary | 1973 |
| Mr. Roy Galvin | Executive VP & Chief Commercial Officer | 1970 |
| Ms. Farris Maryanne E. Maunsell | VP, Chief Accounting Officer & Principal Accounting Officer | 1976 |
| Ms. Olga Guyette | VP of IR & Treasury | — |
| Mr. Josh Gitelson | Senior Director of Global Communications | — |
| Mr. Rajeev Varma | Senior Vice President of Strategy & Corporate Development | — |
| Ms. Laurie A. Miller | Senior VP & Chief Human Resources Officer | 1974 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 12, 2026
Technical indicators
- RSI 14
- 74.50
- MACD 12/26/9
- 2.76
- EMA 9 of MACD
- 2.02
- MACD histogram
- 0.74
- SMA 50
- $101.61
- Price above SMA 50
- EMA 50
- $100.60
- Price above EMA 50
- SMA 200
- $75.75
- Price above SMA 200
- EMA 200
- $81.25
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $86.00
- Average
- $123.29
- High
- $140.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.7 | -27.6 | +5.7 | |||||||||
| 2022 | -11.6 | +18.2 | +9.9 | -20.6 | +24.5 | +4.6 | +3.2 | +9.0 | -0.5 | +12.0 | +1.6 | -7.3 |
| 2023 | +9.6 | -7.8 | +7.2 | +1.1 | +2.1 | -1.7 | +10.0 | -2.7 | -0.7 | -3.3 | -6.4 | +1.5 |
| 2024 | -10.2 | -6.4 | +15.1 | +8.4 | -8.7 | -2.7 | +8.8 | -16.1 | +7.1 | -9.9 | +22.4 | -10.7 |
| 2025 | -11.9 | -1.0 | -2.4 | +0.0 | +7.5 | +8.5 | -3.0 | -27.1 | -9.0 | +2.5 | +61.8 | -1.0 |
| 2026 | -16.7 | -3.7 | -11.8 | +6.8 | +14.4 | +11.6 | +14.3 | +18.8 | +3.3 | +13.7 |
